Dr Corp Ltd
SZSE:301177
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 5-Year Average (10.5), the stock would be worth ¥1.07 (96% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 279.3 | ¥28.65 |
0%
|
| 5-Year Average | 10.5 | ¥1.07 |
-96%
|
| Industry Average | 11.6 | ¥1.19 |
-96%
|
| Country Average | 28.9 | ¥2.96 |
-90%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
¥7.5B
|
/ |
Oct 2025
¥26.4m
|
= |
|
|
¥7.5B
|
/ |
Dec 2025
¥396.9m
|
= |
|
|
¥7.5B
|
/ |
Dec 2026
¥760.8m
|
= |
|
|
¥7.5B
|
/ |
Dec 2027
¥229.8m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
D
|
Dr Corp Ltd
SZSE:301177
|
11.5B CNY | 279.3 | 84.7 | |
| FR |
|
LVMH Moet Hennessy Louis Vuitton SE
PAR:MC
|
234.1B EUR | 14.2 | 21.4 | |
| FR |
|
Hermes International SCA
PAR:RMS
|
172.8B EUR | 24.3 | 38.2 | |
| KR |
|
SBW
KRX:102280
|
235.5T KRW | -58 109.2 | -117 637.1 | |
| CH |
|
Compagnie Financiere Richemont SA
SIX:CFR
|
88.4B CHF | 20.2 | 23.9 | |
| FR |
|
EssilorLuxottica SA
PAR:EL
|
86B EUR | 28.2 | 37.2 | |
| FR |
|
Christian Dior SE
PAR:CDI
|
80.1B EUR | 5.9 | 17.6 | |
| IN |
|
Titan Company Ltd
NSE:TITAN
|
3.9T INR | 57 | 82.7 | |
| FR |
|
Kering SA
PAR:KER
|
29.4B EUR | 24.9 | 416.7 | |
| CN |
|
ANTA Sports Products Ltd
HKEX:2020
|
233.4B HKD | 10.1 | 14.9 | |
| US |
|
Tapestry Inc
NYSE:TPR
|
29.6B USD | 19.2 | 56.6 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Dr Corp Ltd
Glance View
In the bustling world of digital transformation, Dr Corp Ltd. has carved out its niche as an innovative leader that specializes in providing advanced software solutions tailored for the healthcare industry. Born out of a vision to streamline medical processes, the company has grown to become a pivotal player in the intersection of technology and medicine. At its core, Dr Corp Ltd. focuses on developing cutting-edge electronic health record systems, telemedicine platforms, and data analytics tools that aim to enhance patient care, streamline operations, and reduce costs for healthcare providers. Their suite of solutions is designed to integrate seamlessly into existing hospital infrastructure, offering medical practitioners intuitive tools for better data management and patient interaction. The revenue model of Dr Corp Ltd. is as sophisticated as its technology, embracing both subscription-based and licensing fees that provide a steady stream of income. Healthcare establishments often subscribe to Dr Corp's flagship software, drawn by its flexibility and ability to scale according to organizational needs. The company also capitalizes on its consulting services, offering bespoke solutions that include training and support to optimize the use of its products. This dual-pronged approach ensures a diversified income stream, allowing Dr Corp Ltd. to continually invest in research and development, staying ahead of technological curves and adapting to the ever-evolving demands of the healthcare industry. As a result, the firm maintains its reputation not only as a service provider but as a crucial partner in healthcare innovations.